AI Article Synopsis
- Obesity leads to various health issues that impact different areas of medicine.
- The causes of these health issues include factors like chronic inflammation, insulin resistance, and hormonal changes.
- Understanding how these mechanisms interact can help in treating obesity-related health conditions and directing future research.
Article Abstract
Obesity is associated with a wide range of comorbidities that transverse multiple specialties in clinical medicine. The development of these comorbidities is driven by various mechanistic changes including chronic inflammation and oxidative stress, increased growth-promoting adipokines, insulin resistance, endothelial dysfunction, direct loading and infiltrative effect of adiposity, heightened activities of the renin-angiotensin-aldosterone system and sympathetic nervous system, impaired immunity, altered sex hormones, altered brain structure, elevated cortisol levels, and increased uric acid production, among others. Some of the comorbidities might develop secondary to one or more other comorbidities. Considering the obesity-associated comorbidities in the context of the mechanistic changes is helpful in understanding these conditions and in guiding treatment and future research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.gtc.2023.03.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The First Triple Agonist for Antiobesity: Retatrutide.
Cardiol Rev
October 2024
From the School of Medicine, New York Medical College, Valhalla, NY.
The prevalence of individuals with overweight and obesity has increased by 18% since 1990 and it is projected that by 2030, nearly 50% of US adults will have obesity. Lifestyle modifications, such as diet and exercise, typically lead to approximately 3-5% weight loss, whereas 5-15% weight loss is necessary to significantly impact obesity-associated comorbidities and improve overall health outcomes. In addition to lifestyle modifications, pharmacotherapy has been utilized as an adjunctive treatment to increase weight loss and improve health outcomes.
View Article and Find Full Text PDFGut Microbiota-microRNA Interactions and Obesity Pathophysiology: A Systematic Review of Integrated Studies.
Int J Mol Sci
November 2024
Department of Kinesiology and Sport Management and Obesity Research Institute, Texas Tech University, Lubbock, TX 79409, USA.
Obesity is the fifth leading cause of death globally and its comorbidities put a high burden on societies and cause disability. In this review, we aim to summarize the interactions and crosstalk between gut microbiota and micro-RNA (miRNA) in obesity. We searched for the relevant literature through PubMed, Web of Science, Scopus, and Science Direct.
View Article and Find Full Text PDFPostbiotics for the management of obesity, insulin resistance/type 2 diabetes and NAFLD. Beyond microbial viability.
Crit Rev Food Sci Nutr
December 2024
Nutrition and Obesity Group, Department of Nutrition and Food Science, Faculty of Pharmacy and Lucio Lascaray Research Centre, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain.
Highly prevalent comorbidities associated with metabolic syndrome, such as abdominal obesity, nonalcoholic fatty liver disease (NAFLD) and insulin-resistance/Type 2 diabetes (IR/T2D) share alterations in gut microbiota composition as a potential triggering factor. Recent studies put the attention in the potential usage of postbiotics (inactivated probiotics) on these metabolic alterations. This review summarizes the current evidence regarding the efficacy of postbiotic administration in both, preclinical and clinical studies, for the management of obesity, NAFLD and IR/T2D.
View Article and Find Full Text PDFImpact of Sleeve Gastrectomy on Body Weight and Food Intake Regulation in Diet-Induced Obese Mice.
Curr Issues Mol Biol
November 2024
Obesity and Comorbidities Research Center (OCRC), Department of Structural and Functional Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas 13083864, SP, Brazil.
The epidemic of obesity has increased worldwide and is associated with comorbidities such as diabetes and cardiovascular disease. In this context, strategies that modulate body weight and improve glycemic metabolism have increased, and bariatric surgeries such as Sleeve Gastrectomy (SG) have been highlighted in obesity treatment. However, the mechanism by which SG reduces body weight and improves glycemic control remains unknown.
View Article and Find Full Text PDFGastric Pouch Resizing for Recurrent Weight Gain After Roux-en-Y Gastric Bypass-Does It Have Its Rational?
Obes Surg
December 2024
Department of Visceral and Transplant Surgery, Swiss HPB Center, University Hospital Zurich, 8091, Zurich, Switzerland.
Article Synopsis
- Metabolic-bariatric surgery (MBS) is the best treatment for obesity, but many patients experience recurrent weight gain after Roux-en-Y gastric bypass (RYGB), leading to associated health issues; gastric pouch resizing (GPR) offers a low-risk solution for this weight regain.
- A study involving 48 patients who underwent GPR after RYGB showed significant weight stabilization over time, with a mean follow-up indicating an improvement in BMI and resolution of obesity-related health conditions in more than half of the participants.
- The procedure was determined to be safe, with low rates of complications, and patients reported high satisfaction levels, making GPR a worthwhile option for those struggling with weight regain post-surgery.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!